Reneo Pharmaceuticals Raises $95 Million in Series B Financing, Co-led by Novo Ventures and Abingworth

Reneo Receives Orphan Drug Designations from the EMA for REN001 for the Treatment of LCHAD Deficiency and MELAS Syndrome and Moves Forward with Clinical Trials

Restoring Cellular Power Outages: A New Drug Candidate to Treat Mitochondrial Disease